126 related articles for article (PubMed ID: 24829953)
1. [Treatment of myopic choroidal neovascularization: recommendations of the Fédération France Macula].
Leveziela N; Quaranta-El Maftouhib M; Lalloumc F; Souied É; Cohen SY;
J Fr Ophtalmol; 2014 Apr; 37(4):320-8. PubMed ID: 24829953
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor inhibitor use and treatment approach for choroidal neovascularization secondary to pathologic myopia.
Pakzad-Vaezi K; Mehta H; Mammo Z; Tufail A
Expert Opin Biol Ther; 2016 Jul; 16(7):873-81. PubMed ID: 26985834
[TBL] [Abstract][Full Text] [Related]
3. Translocation of the macula for management of subfoveal choroidal neovascularization: comparison of results in age-related macular degeneration and degenerative myopia.
Glacet-Bernard A; Simon P; Hamelin N; Coscas G; Soubrane G
Am J Ophthalmol; 2001 Jan; 131(1):78-89. PubMed ID: 11162982
[TBL] [Abstract][Full Text] [Related]
4. Choroidal neovascularization in pathological myopia.
Neelam K; Cheung CM; Ohno-Matsui K; Lai TY; Wong TY
Prog Retin Eye Res; 2012 Sep; 31(5):495-525. PubMed ID: 22569156
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia.
Ohno-Matsui K; Ikuno Y; Lai TYY; Gemmy Cheung CM
Prog Retin Eye Res; 2018 Mar; 63():92-106. PubMed ID: 29111299
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for myopic choroidal neovascularization.
Ng DS; Kwok AK; Chan CW
Clin Exp Ophthalmol; 2012; 40(1):e98-e110. PubMed ID: 21902785
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis.
Wang E; Chen Y
Retina; 2013; 33(7):1375-92. PubMed ID: 23514793
[TBL] [Abstract][Full Text] [Related]
8. The other CNVM: a review of myopic choroidal neovascularization treatment in the age of anti-vascular endothelial growth factor agents.
Adatia FA; Luong M; Munro M; Tufail A
Surv Ophthalmol; 2015; 60(3):204-15. PubMed ID: 25890624
[TBL] [Abstract][Full Text] [Related]
9. Natural history of choroidal neovascularization in high myopia.
Miller DG; Singerman LJ
Curr Opin Ophthalmol; 2001 Jun; 12(3):222-4. PubMed ID: 11389351
[TBL] [Abstract][Full Text] [Related]
10. Choroidal neovascularisation in pathological myopia: an update in management.
Chan WM; Ohji M; Lai TY; Liu DT; Tano Y; Lam DS
Br J Ophthalmol; 2005 Nov; 89(11):1522-8. PubMed ID: 16234465
[TBL] [Abstract][Full Text] [Related]
11. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
[TBL] [Abstract][Full Text] [Related]
12. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
14. CHOROIDAL THICKNESS AND CHORIORETINAL ATROPHY IN MYOPIC CHOROIDAL NEOVASCULARIZATION WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Kim SH; Koh HJ; Kim SS; Byeon SH; Lee CS
Retina; 2017 Aug; 37(8):1516-1522. PubMed ID: 27798519
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
16. Antivascular endothelial growth factor for choroidal neovascularization in pathologic myopia.
Battaglia Parodi M; Iacono P; Bandello F
Dev Ophthalmol; 2010; 46():73-83. PubMed ID: 20703033
[TBL] [Abstract][Full Text] [Related]
17. [Statement of the German Ophthalmological Society, the Retina Society and the Professional Association of German Ophthalmologists therapy for choroidal neovascularization in myopia ].
Pauleikhoff D; Bertram B; Claessens D; ; ;
Klin Monbl Augenheilkd; 2014 May; 231(5):548-53. PubMed ID: 24799174
[No Abstract] [Full Text] [Related]
18. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
[TBL] [Abstract][Full Text] [Related]
19. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
20. Different dosing of intravitreal bevacizumab for choroidal neovascularization because of pathologic myopia.
Wakabayashi T; Ikuno Y; Gomi F
Retina; 2011 May; 31(5):880-6. PubMed ID: 21242860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
